Abstract
Background: Oxaliplatin /5-FU-based regimens have become the standard of care for colon cancer in the adjuvant setting in recent years. As the benefits and outcomes of these regimens in clinical practice is not widely known, the ACCElox registry was set up to assess the therapeutic management of early stage colon cancer with oxaliplatin/5-FU-based regimen and the duration of adjuvant chemotherapy in current clinical practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
